NCT04458922 2026-04-13
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)